• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Nitrobenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Nitrobenzoic acids and derivatives

Recent Advances in the Study of 3-Nitro-4-(propylamino)benzoic Acid (CAS: 68740-31-8): A Comprehensive Research Brief

The compound 3-Nitro-4-(propylamino)benzoic acid (CAS: 68740-31-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This aromatic nitro compound, characterized by its unique structural features, has shown promising potential in various applications, including drug development and biochemical studies. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and potential therapeutic applications, making it a compound of considerable interest to researchers in the field.

One of the key areas of investigation has been the synthesis and optimization of 3-Nitro-4-(propylamino)benzoic acid. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that improves yield and purity while reducing the environmental impact of the production process. The researchers employed a combination of catalytic hydrogenation and selective nitration, achieving a yield of over 85% with high purity. This advancement is particularly significant for scaling up production for potential industrial applications.

In terms of pharmacological activity, recent in vitro studies have demonstrated that 3-Nitro-4-(propylamino)benzoic acid exhibits notable inhibitory effects on specific enzymatic pathways. For instance, a 2024 study in Bioorganic & Medicinal Chemistry Letters reported its potent inhibition of cyclooxygenase-2 (COX-2), suggesting potential anti-inflammatory applications. The compound's ability to modulate inflammatory markers without significant cytotoxicity makes it a promising candidate for further development as a non-steroidal anti-inflammatory drug (NSAID).

Furthermore, computational modeling studies have provided insights into the molecular interactions of 3-Nitro-4-(propylamino)benzoic acid with biological targets. Molecular docking simulations revealed strong binding affinities to several protein targets involved in metabolic regulation, hinting at potential applications in metabolic disorder therapeutics. These findings were corroborated by in vivo studies in animal models, where the compound showed measurable effects on glucose metabolism and lipid profiles.

The safety profile of 3-Nitro-4-(propylamino)benzoic acid has also been a focus of recent research. Toxicological assessments conducted in 2023 indicated favorable pharmacokinetic properties with minimal off-target effects at therapeutic doses. However, researchers have noted the need for further studies to fully characterize its long-term safety and potential drug-drug interactions before advancing to clinical trials.

Looking forward, the research community anticipates several directions for future investigation. These include exploring structure-activity relationships through derivative synthesis, investigating combination therapies with existing medications, and developing more efficient large-scale synthesis methods. The compound's versatility and demonstrated biological activities position it as a valuable scaffold for future drug discovery efforts in multiple therapeutic areas.

• 59320-41-1(4-(2-aminoethyl)amino-3-nitrobenzoic Acid)
• 1219964-15-4(4-{3-(Dimethylamino)propylamino}-3-nitrobenzoic acid hydrochloride)
• 284672-95-3(4-(Isopropylamino)-3-nitrobenzoic acid)
• 59320-14-8(4-(2-Hydroxyethyl)amino-3-nitrobenzoic Acid)
• 120321-65-5(4-(Butylamino)-3-nitrobenzoic acid)
• 234751-05-4(Benzoic acid, 4-[(2-methylpropyl)amino]-3-nitro-)
• 94160-44-8(Benzoic acid,4-(methyloctadecylamino)-3-nitro-)
• 2347-38-8(Benzoic acid,4-(dipropylamino)-3,5-dinitro-)
• 123557-14-2(Benzoic acid, 3-nitro-4-[(2-phenylethyl)amino]-)
• 2788-74-1(4-(Ethylamino)-3-nitrobenzoic acid)